A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia

Louise Thorlacius-Ussing*, Patrick Terrence Brooks, Henrik Nielsen, Bitten Aagaard Jensen, Lothar Wiese, Susanne Gjørup Sækmose, Stine Johnsen, Mikkel Gybel-Brask, Isik S. Johansen, Mie Topholm Bruun, Nina Breinholdt Stærke, Lars Østergaard, Christian Erikstrup, Sisse Rye Ostrowski, Keld Mikkelsen Homburg, Jørgen Georgsen, Susan Mikkelsen, Håkon Sandholdt, Cæcilie Leding, Nichlas HovmandClara Lundetoft Clausen, Michaela Tinggaard, Karen Brorup Heje Pedersen, Katrine Kjær Iversen, Sandra Tingsgård, Simone Bastrup Israelsen, Thomas Benfield

*Kontaktforfatter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

3 Downloads (Pure)

Abstrakt

Passive immunotherapy with convalescent plasma may be the only available agent during the early phases of a pandemic. Here, we report safety and efficacy of high-titer convalescent plasma for COVID-19 pneumonia. Double-blinded randomized multicenter placebo-controlled trial of adult patients hospitalized with COVID-19 pneumonia. The intervention was COVID-19 convalescent plasma and placebo was saline allocated 2:1. The primary outcome was clinical status 14 days after the intervention evaluated on a clinical ordinal scale. The trial was registered at ClinicalTrials.Gov, NCT04345289, 14/04/2020. The CCAP-2 trial was terminated prematurely due to futility. Of 147 patients randomized, we included 144 patients in the modified intention-to-treat population. The ordinal clinical status 14 days post-intervention was comparable between treatment groups (odds ratio (OR) 1.41, 95% confidence interval (CI) 0.72-2.09). Results were consistent when evaluating clinical progression on an individual level 14 days after intervention (OR 1.09; 95% CI 0.46-1.73). No significant differences in length of hospital stay, admission to ICU, frequency of severe adverse events or all-cause mortality during follow-up were found between the intervention and the placebo group. Infusion of convalescent plasma did not influence clinical progression, survival or length of hospitalization in patients with COVID-19 pneumonia.

OriginalsprogEngelsk
Artikelnummer16385
TidsskriftScientific Reports
Vol/bind12
Udgave nummer1
Antal sider8
ISSN2045-2322
DOI
StatusUdgivet - 30 sep. 2022

Bibliografisk note

© 2022. The Author(s).

Fingeraftryk

Dyk ned i forskningsemnerne om 'A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia'. Sammen danner de et unikt fingeraftryk.

Citationsformater